NCT06865040View on ClinicalTrials.gov

Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

NANot yet recruitingINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2028

Conditions
Thoracic SurgeryPostoperative Pulmonary Complications (PPCs)
Interventions
DRUG

Formoterol Fumarate 12 mcg (Foradil Aerolizer)

"Administration in the interventional arm of long-acting inhaled ß-2 mimetics:~FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7."

OTHER

Usual treatment

usual treatment

Trial Locations (1)

80054

CHRU Amiens, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT06865040 - Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications | Biotech Hunter | Biotech Hunter